【港股通】翰森製藥(03692)午後升近4% 新型ADC藥物獲臨牀試驗批准及優先藥物認定

金吾財訊

2024-12-18

金吾財訊 | 翰森製藥(03692)臨近午盤發力，午後升幅擴大，截至發稿，漲3.82%，報18.46港元，成交額6416.03萬港元。公司日前公告，於2024年12月16日，集團自主研發的新型抗體–藥物偶聯物(ADC)注射用HS-20110獲中國國家藥品監督管理局(NMPA)簽發的藥物臨牀試驗批准通知書，擬開展用於晚期實體瘤的臨牀試驗。另外，公司近日公告，GSK就GSK5764227(GSK’227，亦稱 HS-20093)獲歐洲藥品管理局(EMA)優先藥物(PRIME)認定，此B7-H3靶向抗體藥物偶聯物(ADC)正在評估用於復發廣泛期小細胞肺癌(ES-SCLC)患者的治療。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2492924420"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492924420\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2492924420?lang=zh_TW&edition=fundamental","thumbnail":"https://static.szfiu.com/news/20241105/OGZjY2Y5NjEzNTIxNjU5NDU5.jpg","is_english":false,"pubTime":"2024-12-18 13:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492924420","market":"sh","top_or_hot":-1,"title":"【港股通】翰森製藥(03692)午後升近4% 新型ADC藥物獲臨牀試驗批准及優先藥物認定","media":"金吾財訊","content":"<html><body><p>金吾財訊 | <a href=\"https://laohu8.com/S/03692\">翰森製藥</a>(03692)臨近午盤發力，午後升幅擴大，截至發稿，漲3.82%，報18.46港元，成交額6416.03萬港元。公司日前公告，於2024年12月16日，集團自主研發的新型抗體–藥物偶聯物(ADC)注射用HS-20110獲中國國家藥品監督管理局(NMPA)簽發的藥物臨牀試驗批准通知書，擬開展用於晚期實體瘤的臨牀試驗。另外，公司近日公告，GSK就GSK5764227(GSK’227，亦稱 HS-20093)獲歐洲藥品管理局(EMA)優先藥物(PRIME)認定，此B7-H3靶向抗體藥物偶聯物(ADC)正在評估用於復發廣泛期小細胞肺癌(ES-SCLC)患者的治療。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>【港股通】翰森製藥(03692)午後升近4% 新型ADC藥物獲臨牀試驗批准及優先藥物認定</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【港股通】翰森製藥(03692)午後升近4% 新型ADC藥物獲臨牀試驗批准及優先藥物認定\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086022552\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">金吾財訊 </p>\n<p class=\"h-time smaller\">2024-12-18 13:47</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>金吾財訊 | <a href=\"https://laohu8.com/S/03692\">翰森製藥</a>(03692)臨近午盤發力，午後升幅擴大，截至發稿，漲3.82%，報18.46港元，成交額6416.03萬港元。公司日前公告，於2024年12月16日，集團自主研發的新型抗體–藥物偶聯物(ADC)注射用HS-20110獲中國國家藥品監督管理局(NMPA)簽發的藥物臨牀試驗批准通知書，擬開展用於晚期實體瘤的臨牀試驗。另外，公司近日公告，GSK就GSK5764227(GSK’227，亦稱 HS-20093)獲歐洲藥品管理局(EMA)優先藥物(PRIME)認定，此B7-H3靶向抗體藥物偶聯物(ADC)正在評估用於復發廣泛期小細胞肺癌(ES-SCLC)患者的治療。</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"1949878","article_id":"2492924420","we_media_id":"1086022552","thumbnails":["https://static.szfiu.com/news/20241105/OGZjY2Y5NjEzNTIxNjU5NDU5.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492924420","pubTimestamp":1734500849,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"金吾財訊","introduction":"「金吾财讯」以精准用户需求为切入点，打造一站式港美股投资细分领域品牌。依托战略合作伙伴凤凰网财经，将港美股内容传播到全球华人圈。","home_visible":1,"id":"1086022552","head_image":"https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c"},"summary":"金吾財訊 | 翰森製藥(03692)臨近午盤發力，午後升幅擴大，截至發稿，漲3.82%，報18.46港元，成交額6416.03萬港元。公司日前公告，於2024年12月16日，集團自主研發的新型抗體–藥物偶聯物(ADC)注射用HS-20110獲中國國家藥品監督管理局(NMPA)簽發的藥物臨牀試驗批准通知書，擬開展用於晚期實體瘤的臨牀試驗。另外，公司近日公告，GSK就GSK5764227(GSK’227，亦稱 HS-20093)獲歐洲藥品管理局(EMA)優先藥物(PRIME)認定，此B7-H3靶向抗體藥物偶聯物(ADC)正在評估用於復發廣泛期小細胞肺癌(ES-SCLC)患者的治療。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","03347":"泰格医药","BK4080":"零售业房地产投资信托","HSCEI":"国企指数","03692":"翰森制药","BK4231":"零售房地产信托","BK1191":"制药","BK1589":"北水核心资产","ADC":"艾格里房产","YANG":"三倍做空富时中国ETF-Direxion","BK1141":"生命科学工具和服务","HSTECH":"恒生科技指数","BK1576":"医药外包概念"},"translate_title":"[Hong Kong Stock Connect] Hansoh Pharmaceutical (03692) rose nearly 4% in the afternoon, and its new ADC drug was approved for clinical trials and designated as a priority drug","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03347":1,"03692":1,"ADC":1,"HSCEI":1,"HSTECH":1,"YANG":1},"content_text":"金吾財訊 | 翰森製藥(03692)臨近午盤發力，午後升幅擴大，截至發稿，漲3.82%，報18.46港元，成交額6416.03萬港元。公司日前公告，於2024年12月16日，集團自主研發的新型抗體–藥物偶聯物(ADC)注射用HS-20110獲中國國家藥品監督管理局(NMPA)簽發的藥物臨牀試驗批准通知書，擬開展用於晚期實體瘤的臨牀試驗。另外，公司近日公告，GSK就GSK5764227(GSK’227，亦稱 HS-20093)獲歐洲藥品管理局(EMA)優先藥物(PRIME)認定，此B7-H3靶向抗體藥物偶聯物(ADC)正在評估用於復發廣泛期小細胞肺癌(ES-SCLC)患者的治療。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0}}}